SS109 / Gensciences - LARVOL DELTA

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (clinicaltrials.gov) - P1/2 | N=24 | Completed | Sponsor: Jiangsu Gensciences lnc. | Recruiting ➔ Completed

Trial completion • Hematological Disorders • Hemophilia • Rare Diseases

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Jiangsu Gensciences lnc. | Trial primary completion date: Jan 2024 ➔ May 2024

Trial primary completion date • Hematological Disorders • Hemophilia • Rare Diseases

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Jiangsu Gensciences lnc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia • Rare Diseases

SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Jiangsu Gensciences lnc.

New P1/2 trial • Hematological Disorders • Hemophilia • Rare Diseases

A Phase I of SS109 in Hemophilia A or and B With Inhibitors (clinicaltrials.gov) - P1 | N=27 | Completed | Sponsor: Jiangsu Gensciences lnc. | Active, not recruiting ➔ Completed

Trial completion • Hematological Disorders • Hemophilia • Rare Diseases

A Phase I of SS109 in Hemophilia A or and B With Inhibitors (clinicaltrials.gov) - P1 | N=27 | Active, not recruiting | Sponsor: Jiangsu Gensciences lnc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Disorders • Hemophilia • Rare Diseases

A Phase I of SS109 in Hemophilia A or and B With Inhibitors (clinicaltrials.gov) - P1 | N=27 | Recruiting | Sponsor: Jiangsu Gensciences lnc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia • Rare Diseases

A Phase I of SS109 in Hemophilia A or and B With Inhibitors (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Jiangsu Gensciences lnc.

New P1 trial • Hematological Disorders • Hemophilia • Rare Diseases